Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
- Details
- Category: Novartis

New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
- Details
- Category: AstraZeneca

Ebola vaccine trials fast-tracked by international consortium
- Details
- Category: GlaxoSmithKline

Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen
- Details
- Category: Pfizer

Roche and InterMune reach definitive merger agreement
- Details
- Category: Roche

Novartis provides drug candidate compounds to TB Alliance
- Details
- Category: Novartis

United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
- Details
- Category: AstraZeneca

More Pharma News ...
- FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
- Sanofi and MannKind announce global licensing agreement for Afrezza® (insulin human) rapid-acting inhaled insulin
- Allied Minds and Bristol-Myers Squibb form new enterprise
- Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines
- Pfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
- AstraZeneca agrees strategic transaction with Almirall in respiratory disease
- Bayer continues positive business development